Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Disclosures: JSM has served on the advisory board for Millennium, Celgene, Novartis, Onyx, Janssen, BMS & MSD; KW reports personal fees and non-financial support from Celgene, BMS, Onyx, Amgen & Janssen, grants from Celgene, personal fees from Noxxon; KS reports manuscript preparation for Celgene, served on the advisory board for Celgene Canada; MD has served on the advisory board and received lecture fees, from Celgene & Janssen, received research funding from Celgene; LK served on the advisory board for Celgene. Amgen & Sandoz, received personal fees from Janssen and Gilead; HG research funding from Janssen-Cilag, Celgene, Novartis, Chugai, served on Speaker’s Bureau for Janssen-Cilag, Celgene, Novartis, Onyx, Millennium & from Chugai, received honoraria and consultancy from Janssen-Cilag, Celgene, Novartis, Onyx, Millennium; PM has received personal fees from Celgene, Janssen & Takeda; AB, LG, JML & VL have nothing to disclose; AO has been member of advisory boards or consultant for Janssen, Celgene and Amgen; MC reports consultancy, honoraria & served on Speaker’s Bureau for Celgene; AA reports member of advisory boards for Janssen, Celgene and Amgen; CC received honoraria and research funding from Celgene; CR has received honoraria & travel support from Celgene; NJB reports research funding from Celgene; XY is employed by the Celgene and received stock options yearly as part of compensation; TT, LS, CJ, MZ are all employees of Celgene; MAD has reported financial activities outside the submitted work for Celgene, Janssen, Onyx and Novartis.

Contributions: KW JSM, MAD, PM, LS, Zaki, CJ all made substantial contributions to the conception of the work; AA, CR, KW, HG, JSM, XY, MAD, PM, LS, MZ, CJ all made substantial contributions to the design of the work; NJB, KW, KS, CC, HG, HK, AO, MD, VI, JSM, XY, MAD, AB, JML, TT, PM, LS, MZ, CJ performed acquisition, analysis, or interpretation of data for the work; CR, NJB, KW, KS, AO, JSM, MAD, LS, MZ, CJ contributed to the drafting of the work; AA, CR, NJB, KW, LG, KS, CC, HG, HK, AO, MD, JSM, MAD, JML, PM, LS, MZ, CJ revised the manuscript critically for important intellectual content; AA, CR, NJB, KW, LG, KS, CC, HG, HK, AO, JSM, XY, MAD, AB, JML, TT, PM, LS, MZ, CJ gave final approval of the manuscript to be published; AA, NJB, KW, KS, CC, HG, HK, AO, MD, JSM, MAD, JML, TT, PM, LS, MZ, CJ agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.